Under New CEO, GSK Will Leverage OTCs In Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo will look at opportunities to expand its nonprescription business, as OTC and other products have more long-term sales consistency than Rx drugs, North American Pharmaceuticals President Viehbacher says.
You may also be interested in...
GSK Acts On Cost Plan, Cuts Research Jobs
U.K. firm’s busy spring includes internal downsizing, external investments.
In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: